Palogic Value Management L.P. Has $2.94 Million Holdings in Health Catalyst, Inc. $HCAT

Key Points

• Palogic Value Management L.P. increased its stake in Health Catalyst, Inc. by 103.1% during Q1, now owning 650,000 shares valued at approximately $2.94 million.
• Several institutional investors, including SG Americas Securities and Invesco Ltd., have also significantly raised their positions in Health Catalyst, contributing to 85% institutional ownership of the company.
• The average price target for Health Catalyst has been set at $4.73, with recent ratings ranging from "buy" to "hold," reflecting analysts' mixed outlook on the stock.

Palogic Value Management L.P. increased its holdings in shares of Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) by 103.1% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 650,000 shares of the company's stock after purchasing an additional 330,000 shares during the period. Health Catalyst makes up approximately 1.3% of Palogic Value Management L.P.'s holdings, making the stock its 25th largest position. Palogic Value Management L.P. owned 0.93% of Health Catalyst worth $2,944,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Group One Trading LLC raised its holdings in Health Catalyst by 107.6% in the 4th quarter. Group One Trading LLC now owns 4,360 shares of the company's stock valued at $31,000 after acquiring an additional 2,260 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Health Catalyst by 7.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 36,047 shares of the company's stock worth $163,000 after buying an additional 2,624 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Health Catalyst by 8.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 62,443 shares of the company's stock worth $442,000 after buying an additional 4,798 shares in the last quarter. Probity Advisors Inc. raised its holdings in shares of Health Catalyst by 18.3% in the 1st quarter. Probity Advisors Inc. now owns 36,313 shares of the company's stock worth $164,000 after buying an additional 5,621 shares in the last quarter. Finally, ProShare Advisors LLC raised its holdings in shares of Health Catalyst by 52.7% in the 4th quarter. ProShare Advisors LLC now owns 16,854 shares of the company's stock worth $119,000 after buying an additional 5,815 shares in the last quarter. Institutional investors and hedge funds own 85.00% of the company's stock.

Health Catalyst Trading Down 3.4%

Shares of NASDAQ:HCAT traded down $0.11 during midday trading on Friday, hitting $3.13. The company had a trading volume of 776,691 shares, compared to its average volume of 853,648. Health Catalyst, Inc. has a 12 month low of $2.52 and a 12 month high of $9.24. The company has a current ratio of 1.83, a quick ratio of 1.83 and a debt-to-equity ratio of 0.44. The stock has a market cap of $220.27 million, a price-to-earnings ratio of -2.07 and a beta of 1.53. The firm has a fifty day simple moving average of $3.51 and a 200 day simple moving average of $3.86.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on HCAT. BTIG Research reissued a "neutral" rating on shares of Health Catalyst in a report on Friday, September 5th. Cantor Fitzgerald restated a "neutral" rating and set a $4.00 price target (down from $9.00) on shares of Health Catalyst in a research report on Friday, August 8th. Citigroup lowered Health Catalyst from a "buy" rating to a "neutral" rating and decreased their price objective for the company from $6.50 to $3.50 in a research report on Friday, August 8th. Summit Redstone set a $5.00 price objective on Health Catalyst in a research report on Friday, August 29th. Finally, Piper Sandler lowered Health Catalyst from an "overweight" rating to a "neutral" rating and decreased their price objective for the company from $8.00 to $4.00 in a research report on Wednesday, August 27th. Three equities research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $4.73.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.